All In MedTech

FDA Clearance Tracker · P040044-S097

MYNX CONTROL™ Venous Vascular Closure Device (VCD) 6F-12F

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 27, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 27, 2024

Approved

Time to decision

210 days

Received Nov 30, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P040044-S097
Device name
MYNX CONTROL™ Venous Vascular Closure Device (VCD) 6F-12F
Applicant location
Miami Lakes, FL
Received
Nov 30, 2023
Decided
Jun 27, 2024
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P040044

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code MGB

FDA's approval statement

As written in FDA's record.

Approval for the MYNX CONTROL™ Venous Vascular Closure Device (VCD) 6F-12F for expanding the indications to include venous multiple access closure.

Source documents

Other decisions for Cordis US Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.